The relation between of insulin like growth factor II and endometrial carcinoma


  • Hossam Hassan El Sokkary Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria, Egypt
  • Doaa Ibrahim Hashad Department of Clinical Pathology, Faculty of Medicine, Alexandria, Egypt
  • Ahmed Nooman Sallam Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria, Egypt
  • Amal Zaki Azzam Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria, Egypt
  • Mohamed Ebied Abo Koura Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria, Egypt



Endometrial cancer, Insulin like growth factor 2


Background: Endometrial cancer is the most common gynecologic malignancy in the United States and the fourth most common cancer in women. The need of a soft marker that can be used with CA-125 tumor marker for early detection of endometrial cancer and to predict late stages and advanced histopathological grades and to specify the cases who will be managed by complete surgical staging including para aortic and pelvic lymphadenectomy is of great importance. The aim of the study was to evaluate the role of insulin like growth factor 2 in endometrial carcinoma and to correlate it with different histopathological grades of the disease.

Methods: This study was applied on sixty patients with abnormal uterine bleeding and were divided into two groups, Group A included 30 cases of endometrial carcinoma, while Group B included 30 cases complaining of abnormal vaginal bleeding due to other causes as a control group. Serum samples were taken from all patients and estimation of IGF-2 serum levels using ElISA technique was done. Comparison of IGF-2 serum level between both groups and correlation of its levels with different histopathological grades of endometrial cancer group were done.

Results: As regard comparison between both groups and ILGF2 serum level, study results demonstrated that ILGF2 levels ranged between 600.0-1440.0 ng/ml and 40.0-560.0 ng/ml with the mean of 781.33 ng/ml±196.45 and 336.0 ng/ml±212.86 for cases Group A and control Group B respectively. There was a statistically significant difference between the two studied groups regarding ILGF2 serum level (p<0.001). As regards correlation between histopathological grades and ILGF-2 serum level in cases Group A, the study revealed a strong positive correlation.

Conclusions: ILGF-2 can be used as a serum marker for endometroid adenocarcinoma of the body of the uterus and to predict its higher histopathological grades.


Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7.

Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer. 2015;15:396.

Pickard A, McCance DJ. IGF-binding protein 2 - oncogene or tumor suppressor? Front Endocrinol (Lausanne). 2015;6:25.

Livingstone C. IGF2 and cancer. Endocr Relat Cancer. 2013;20(6):R321-39.

Tian F, Yourek G, Shi X, Yang Y. The development of Wilms tumor: from WT1 and microRNA to animal models. Biochim Biophys Acta. 2014;1846(1):180-7.

Geva, Zohar, Bentov, Itay and Fishman, Ami and Werner, Haim and Bruchim, Ilan. (Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. Gynecol Oncol. 2011;121:383-9.

American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 426: The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. Obstet Gynecol. 2009;113(2 Pt 1):462-4.

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.

Sacco A, Morcavallo A, Pandini G, Vigneri R, Belfiore A. Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinol. 2009;150:3594-602.

El Kafrawy NA, Glal AZ, Kandil MA, Eldin Dawood AA, Essa ES, Elgendy DS. A study of the relation between insulin resistance, insulin-like growth factor-1, and malignancy in type 2 diabetic patients. Menoufia Med J. 2015;28:494-502.

Bruchim I, Sarfstein R, Werner H. The IGF Hormonal Network in endometrial cancer: functions, regulation, and targeting approaches. front endocrinol (Lausanne). 2014;5:76.

Wang CF, Zhang G, Zhao LJ, Li XP, Qi WJ, Wang JL, et al. Effects of insulin, insulin-like growth factor-I and -II on proliferation and intracellular signaling in endometrial carcinoma cells with different expression levels of insulin receptor isoform A. Chin Med J. 2013;126(8):1560-6.

Merritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, et al. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes Control. 2016;27(6):737-48.






Original Research Articles